Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.67 |
| ▸ | AHCY | P23526 | 2/20 | 0.61 |
| ▸ | NADK | O95544 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.60 |
| ▸ | DPP4 | P27487 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.60 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.60 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.60 |
| ▸ | GAPDH | P04406 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | STAT6 | P42226 | 1/20 | 0.60 |
| ▸ | PI4KA | P42356 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1553926 | 1.00 | ADORA1 (0.67) | ADORA1AHCYNADKADORA3ADORA2A | |
| SCHEMBL13268819 | 0.88 | ADORA1 (0.68) | ADORA1AHCYNADKADORA3ADORA2A | |
| SCHEMBL13268689 | 0.88 | ADORA1 (0.68) | ADORA1AHCYNADKADORA3ADORA2A | |
| SCHEMBL13269093 | 0.88 | ADORA1 (0.68) | ADORA1AHCYNADKADORA3ADORA2A | |
| SCHEMBL7027633 | 0.88 | ADORA1 (0.69) | ADORA1AHCYNADKADORA3ADORA2A | |
| SCHEMBL7435435 | 0.86 | AHCY (0.71) | ADORA1AHCYNADKADORA3ADORA2A | |
| SCHEMBL10710453 | 0.86 | ADORA1 (0.68) | ADORA1AHCYNADKADORA3ADORA2A | |
| SCHEMBL7872477 | 0.85 | ADORA1 (0.67) | ADORA1AHCYNADKADORA3ADORA2A | |
| SCHEMBL13268621 | 0.85 | AHCY (0.58) | ADORA1AHCYNADKADORA3ADORA2A | |
| Adenosine Phosphate SCHEMBL1050410 | 0.85 | P2RY1 (0.76) | ADORA1SMN1; SMN2DNPH1PRKAB2TRPM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5070877-A | Using adenosin receptor agonist | MEDCO RESEARCH, INC. (US) | 1991-12-10 | — | — | US | claimed |
| EP-0181129-B1 | N6-SUBSTITUTED DEOXYRIBOSE ANALOGS OF ADENOSINES | WARNER-LAMBERT COMPANY (US) | 1989-03-08 | — | — | EP | claimed |
| EP-0181129-A2 | N6-substituted deoxyribose analogs of adenosines | WARNER-LAMBERT COMPANY (US) | 1986-05-14 | — | — | EP | claimed |
| JP-4124143-A | — | — | None | — | — | JP | disclosed |
| EP-1718757-B1 | GLIMEPIRIDE- AND INSULIN-INDUCED GLYCOSYLPHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C REGULATION | SANOFI AVENTIS DEUTSCHLAND (DE) | 2012-03-28 | — | — | EP | disclosed |
| US-8017350-B2 | Glimepiride- and insulin-induced glycosylphosphatidylinositol-specific phospholipase C regulation | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-09-13 | — | — | US | disclosed |
| US-7449560-B2 | Phosophoinositoglycan binding proteins | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-11-11 | — | — | US | disclosed |
| US-20070111263-A1 | GLIMEPIRIDE- AND INSULIN-INDUCED GLYCOSYLPHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C REGULATION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-17 | — | — | US | disclosed |
| EP-1718757-A2 | GLIMEPIRIDE- AND INSULIN-INDUCED GLYCOSYLPHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C REGULATION | Sanofi-Aventis Deutschland GmbH (DE) | 2006-11-08 | — | — | EP | disclosed |
| US-20060160142-A1 | Phosophoinositoglycan binding proteins | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-20 | — | — | US | disclosed |
| US-7049416-B2 | Phosophoinositoglycan binding proteins | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-05-23 | — | — | US | disclosed |
| WO-1998039008-A1 | METHODS AND COMPOSITIONS FOR PROTECTING AGAINST CARDIAC ISCHEMIA BY ADMINISTERING ADENOSINE A2A RECEPTOR ANTAGONISTS | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1998-09-11 | — | — | WO | disclosed |
| JP-H04124143-A | CARDIAC INFARCTION MEDICINE CONTAINING ADENOSINE OR ITS RELATED COMPOUND AS ACTIVE INGREDIENT | MEDCO RES INC | 1992-04-24 | — | — | JP | disclosed |
| US-5070877-A | Using adenosin receptor agonist | MEDCO RESEARCH, INC. (US) | 1991-12-10 | — | — | US | disclosed |
| US-5070877-A | Using adenosin receptor agonist | MEDCO RESEARCH, INC. (US) | 1991-12-10 | — | — | US | disclosed |
| EP-0354638-A3 | USE OF ADENOSINE AND ITS DERIVATIVES IN DIAGNOSIS | MEDCO RESEARCH INC (US) | 1990-09-26 | — | — | EP | disclosed |
| EP-0354638-A2 | Use of adenosine and its derivatives in diagnosis | MEDCO RESEARCH INC (US) | 1990-02-14 | — | — | EP | disclosed |
| EP-0354638-A2 | Use of adenosine and its derivatives in diagnosis | MEDCO RESEARCH INC (US) | 1990-02-14 | — | — | EP | disclosed |
| EP-0181129-B1 | N6-SUBSTITUTED DEOXYRIBOSE ANALOGS OF ADENOSINES | WARNER-LAMBERT COMPANY (US) | 1989-03-08 | — | — | EP | disclosed |
| EP-0181129-A2 | N6-substituted deoxyribose analogs of adenosines | WARNER-LAMBERT COMPANY (US) | 1986-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111263-A1 | GLIMEPIRIDE- AND INSULIN-INDUCED GLYCOSYLPHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C REGULATION | GPR119, GID4, PLD1 | ADORA1 1621/4885AHCY 1348/4885NADK 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.